首页> 外文期刊>PLoS One >Potential biomarker identification for Friedreich’s ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion
【24h】

Potential biomarker identification for Friedreich’s ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion

机译:利用患者细胞和小鼠背根神经节在患者细胞和小鼠背根神经节中使用重叠基因表达模式的潜在生物标志物识别Friedreich的共济失调

获取原文
           

摘要

Friedreich’s ataxia (FA) is a neurodegenerative disease with no approved therapy that is the result of frataxin deficiency. The identification of human FA blood biomarkers related to disease severity and neuro-pathomechanism could support clinical trials of drug efficacy. To try to identify human biomarkers of neuro-pathomechanistic relevance, we compared the overlapping gene expression changes of primary blood and skin cells of FA patients with changes in the Dorsal Root Ganglion (DRG) of the KIKO FA mouse model. As DRG is the primary site of neurodegeneration in FA, our goal was to identify which changes in blood and skin of FA patients provide a 'window' into the FA neuropathomechanism inside the nervous system. In addition, gene expression in frataxin-deficient neuroglial cells and FA mouse hearts were compared for a total of 5 data sets. The overlap of these changes strongly supports mitochondrial changes, apoptosis and alterations of selenium metabolism. Consistent biomarkers were observed, including three genes of mitochondrial stress (MTIF2, ENO2), apoptosis (DDIT3/CHOP), oxidative stress (PREX1), and selenometabolism (SEPW1). These results prompted our investigation of the GPX1 activity as a marker of selenium and oxidative stress, in which we observed a significant change in FA patients. We believe these lead biomarkers that could be assayed in FA patient blood as indicators of disease severity and progression, and also support the involvement of mitochondria, apoptosis and selenium in the neurodegenerative process.
机译:Friedreich的Ataxia(FA)是一种神经变性疾病,没有经批准的治疗,这是Frataxin缺乏的结果。鉴定与疾病严重程度和神经病理学机制有关的人对血液生物标志物可以支持药物疗效的临床试验。为了鉴定神经病理学相关性的人体生物标志物,我们将FA患者的重叠基因表达变化与KIKO FA小鼠模型的背根神经节(DRG)的变化进行了变化。由于DRG是FA神经变性的主要部位,我们的目标是确定FA患者的血液和皮肤的变化为神经系统内的FA神经病理学机制提供了“窗口”。此外,比较了脱脂型神经性气囊细胞的基因表达和FA小鼠心脏总共5个数据集。这些变化的重叠强烈支持线粒体改变,细胞凋亡和硒代谢的改变。观察到一致的生物标志物,包括三个线粒体应激(MTIF2,ENO2),细胞凋亡(DDIT3 / Chec),氧化应激(PREX1)和硒素(SEPW1)的三种基因。这些结果促进了我们对硒和氧化应激的标志物的GPX1活性调查,其中我们观察到FA患者的重大变化。我们相信这些铅生物标志物可以在足总患者中作为疾病严重程度和进展的指标进行测定,并且还支持线粒体,细胞凋亡和硒参与神经变性过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号